Caries increment, surface index D(M)FS · Infants/young children (primary teeth; baseline about 1 to 3 years)
1 finding from 1 review
Leiomyoma volume (mL) · patients with uterine fibroids
1 finding from 1 review
Uterine volume (cm³) · patients with uterine fibroids
1 finding from 1 review
Relief of bleedingdichotomic · patients with uterine fibroids
Mifepristone (10 mg/day/3 months) may leads to higher relief of bleedingdichotomic compared with placebo (low certainty).
1 finding from 1 review
Relief of pelvic paindichotomic · patients with uterine fibroids
Mifepristone (10 mg/day/3 months) showed no clear difference in relief of pelvic paindichotomic compared with placebo (low certainty).
1 finding from 1 review
Relief of dysmenorrhoeadichotomic · patients with uterine fibroids
Mifepristone (10 mg/day/3 months) may leads to higher relief of dysmenorrhoeadichotomic compared with placebo (low certainty).
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).
1 finding from 1 review
Adverse effects · People with American cutaneous and mucocutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous and mucocutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported improvement of hirsutism ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who reported an adverse event · women with hirsutism
1 finding from 1 review
Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with hirsutism
1 finding from 1 review
Change in serum androgen levels · women with hirsutism
1 finding from 1 review
Change in BMI · women with hirsutism
1 finding from 1 review
Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) probably leads to higher complete cure, at least 3 months after the end of treatment compared with placebo (same regimen) (moderate certainty).
1 finding from 1 review
Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with placebo (same regimen) (moderate certainty).
1 finding from 1 review
Recurrence · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) showed no clear difference in recurrence compared with placebo (same regimen) (low certainty).
1 finding from 1 review
Adverse effects (narrative) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months)
SoF4. Adverse effects: single study narratively reported 4 participants (20%) in the bethanechol arm experienced adverse events (nausea, dizziness, blood pressure fall, cold perspiration or sporadic abdominal pain);…
1 study · 40 participants
Very low